Search Results - Garbern, J.Y.

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex®), IFNβ-1b (Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing – remitting multiple sclerosis: results after 18 months of therapy

    A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex®), IFNβ-1b (Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing – re... by Khan, O.A., Tselis, A.C., Kamholz, J.A., Garbern, J.Y., Lewis, R.A., Lisak, R.P.

    Published in Multiple sclerosis
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    α-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid-mediated excitotoxic axonal damage is attenuated in the absence of myelin proteolipid protein

    α-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid-mediated excitotoxic axonal damage is attenuated in the absence of myelin proteolipid protein by Fowler, J.H., Edgar, J.M., Pringle, A., McLaughlin, M., McCulloch, J., Griffiths, I.R., Garbern, J.Y., Nave, K.A., Dewar, D.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy

    Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy by Khan, O.A., Zvartau-Hind, M., Caon, C., Din, M.U., Cochran, M., Lisak, D., Tselis, A.C., Kamholz, J.A., Garbern, J.Y., Lisak, R.P.

    Published in Multiple sclerosis
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: